Bio-Rad's DdPCR System Detects Coronavirus More Accurately
Zacks Investment Research | Mar 19, 2020 10:43PM ET
Bio-Rad Laboratories, Inc. (NYSE:BIO) announced that the performance of its QX200 Droplet Digital polymerase chain reaction (PCR) (ddPCR) System for the clinical detection of SARS-CoV-2 was proved to be more accurate compared to the existing testing procedures performed using qPCR. The findings have been published in two studies this month, ahead of peer-review.
Notably, the company is working to provide access to the ddPCR-based tests for the detection of SARS-CoV-2. Bio-Rad is also collaborating with Biodesix in Colorado to bring an Emergency Use Authorization (EUA) test online.
The recent outcomes fortify Bio-Rad’s global Clinical Diagnostics business.
Significance of the Studies
Per the first study, clinicians in Wuhan, China, concluded that a sample of infected individuals, who was initially tested negative for COVID-19 using qPCR, was tested positive using ddPCR. Per the findings, it can be deduced that ddPCR can reduce false-negative results of COVID-19, without leading to an increase in false-positive results. This could be a significant improvement to the current testing standards.
Per the second study, which was led by the National Institute of Metrology and provincial CDCs in China, it was concluded that ddPCR significantly improves the diagnostic detection accuracy of SARS-CoV-2. Additionally, ddPCR was found to be more sensitive and appropriate for those patients in isolation and observation, who are currently not showing any clinical symptoms.
Industry Prospects
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.